about
Successful treatment of extensive posttraumatic soft-tissue and renal infections due to Apophysomyces elegansMulticenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humansVoriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trialAlternatives to antibiotics—a pipeline portfolio reviewAntifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.Importance of Candida species other than Candida albicans as opportunistic pathogens.Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologiesDifferential antifungal activity of isomeric forms of nystatinIn vitro antifungal susceptibilities of Trichosporon species.Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds.In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolatesDefining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.Prospective survey of (1→3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit settingThe evolution of the regulatory framework for antibacterial agentsEvaluation of a method for identification of Candida dubliniensis bloodstream isolatesClinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazoleResistance of Candida species to fluconazoleMicrodilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative studyActivity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice.Disk diffusion-based methods for determining Candida parapsilosis susceptibility to anidulafunginDetermination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia.Invasive candidiasis in immunocompromised hospitalized patients.Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosineQuality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazoleMultisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates.Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B.Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatographyCorrelation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods.Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus speciesAn insight into the antifungal pipeline: selected new molecules and beyond.Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.The challenge of antimicrobial resistance: new regulatory tools to support product development.A comprehensive regulatory framework to address the unmet need for new antibacterial treatments.Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.The value of single-pathogen antibacterial agents.Cunninghamella bertholletiae infection associated with deferoxamine therapy.
P50
Q28242280-F8D9DE57-E2AF-4567-AC72-E620EB319DF0Q28265703-24B57F77-4073-411A-AFEC-5A41F04D77E3Q28278518-637CD371-C651-4524-B4B2-299230ABFB60Q29365161-41C753F8-FF51-4628-BB39-53B8D5E5CAAEQ30452376-712F55C6-5DB9-4E72-BEE5-441CCBD6C6C6Q31905702-3C466F56-FE39-4473-B93D-0CEC4C41B442Q33677651-B1F930F7-CB5B-4217-AA7A-482343EE3AEAQ33983112-32673836-0D6F-455D-97C9-B436F0C8F80EQ34106411-769B9BAC-7F3A-418F-B34F-BF25BA98FBC0Q34152388-3D14C1D8-095E-4B85-824F-0F422F59BB92Q34452652-6F6B9FAE-DEB1-47E4-8499-4821AB34BE70Q34455633-C1DB409D-DEAB-494F-AADE-67602993A013Q34487665-9B2E5011-0C1A-41E2-BD0E-C28EAA97CFB4Q34693386-365DAD7A-8851-4FAD-A886-B84B17DDDA6EQ34746715-A76919B4-3A26-4856-AE0D-BC8FA2B1C109Q34936576-D8798A58-67F6-45E4-8AB6-2DE918E57121Q34941412-1C1D54F9-FE9F-4016-A713-8616ABC957BEQ35110522-84085323-7F77-4B72-BF72-28AB2845AE61Q35128351-C1597950-72AB-4D05-AA92-EA337D59DB37Q35138591-09308158-195C-4290-88DF-FDF7C52EFA06Q35685452-FD32F3CE-1DF9-4468-8E73-4F96C5A1280EQ35745822-AEEA1F82-5B6F-46C2-A3E9-79B15925BA6CQ36018898-2EA1827D-8164-41B1-BD80-C92A78FA96F1Q36282557-EC96E149-ACFD-4DFE-9F0F-65D7AA1B3683Q36521561-AE1F20D7-1947-49E2-AC1B-856EECCC5A26Q36529693-40D6E57B-1C63-47A5-916D-B2EE346115DEQ36534987-E94939C7-27CA-46A9-AB91-5B2725874682Q36542830-763C2D4B-4FC2-4199-BA53-6B5DE754B666Q36753682-EA3C6867-68F2-4136-8964-42E566F42EC0Q36845482-EC89137E-8DB5-4752-8219-17FD0E328063Q37087657-0A9C7C6F-30F4-4470-94A4-567D868BA7FCQ37157546-35644A6C-CA41-48F5-AC63-198DAAD60978Q37781273-05A11B3B-3F55-4F42-8082-26A0CE9EEA3DQ37993043-CA054B90-35E7-4952-91DC-17AFD3028BFBQ38211473-F0C949C9-257B-4443-91C2-75280F6AFAEEQ38410974-EEE82557-0C62-458A-A895-F12A759F57E5Q38795740-42B9110B-59CF-42E1-88D3-17A54D3956CDQ38919690-CBA8FE4C-5860-4E82-A5E5-CF84B418D453Q39309271-7CEAD3B2-9C1E-4430-8466-B8084E29C3FBQ39550186-34C5E1C8-D435-46F5-A54D-36F8FECA73BC
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
J H Rex
@ast
J H Rex
@en
J H Rex
@es
J H Rex
@nl
type
label
J H Rex
@ast
J H Rex
@en
J H Rex
@es
J H Rex
@nl
prefLabel
J H Rex
@ast
J H Rex
@en
J H Rex
@es
J H Rex
@nl
P31
P496
0000-0003-3265-5872